



Product: NT Factor Energy™

Category: Energy

Product No.: RN101

Special Dietary Usefulness

Under a physician's direction, NT Factor Energy™ may have special dietary usefulness for individuals suffering from chronic fatigue syndrome, fibromyalgia and other chronic conditions leaving patients with low energy levels.

Features & Benefits

NT Factor Energy™ is a clinically studied lipid replacement therapy, providing an exogenous means to improve mitochondrial and cellular membrane potential, maximizing membrane fluidity and increasing mitochondrial function.

Features	Constituents	Benefits
NT Factor® Maximum Potency	Polyunsaturated phosphatidylcholine, glycolipids & other polyunsaturated phosphatidyl nutrients; Bifido and Lactobacillus bacterium freeze dried and microencapsulated in a state of suspended animation with potential to form healthy microflora colonies; Growth Media to support microflora colonies	<ul style="list-style-type: none"> • highest potency available • restores membrane health, function, fluidity, and potential (versus antioxidants which only slow down the rate of new damage) • increases energy and mental clarity • increase nutrient absorption from food
Mitochondria Pro Regulator™	Proprietary blend of calcium, phosphorus and magnesium	<ul style="list-style-type: none"> • optimizes mitochondrial function
Krebs Cycle Glucose Absorb™	Proprietary blend of Alpha-ketoglutaric acid and L-Tyrosine	<ul style="list-style-type: none"> • propels the burning of glucose, creating energy and removal of excess ammonia which can cause fatigue
RN Fatty Acid Metabolism™	Proprietary blend of L-carnitine, L-tartrate and pantethine	<ul style="list-style-type: none"> • maximizes ATP production by regulating fatty acid buildup which, if left unchecked, reduces mitochondrial function and increases cellular toxins
Vitamin E	Natural vitamin E (d-alpha tocopherol)	<ul style="list-style-type: none"> • natural antioxidant for nutritional support

Supplement Facts

Serving Size: 2 Tablets

Servings per Container: 45

Amount Per Serving	% Daily Value
Vitamin E (as d-alpha tocopherol)	20 IU 67
NT Factor® Maximum Potency™	1500 mg *
Phosphoglycolipids - includes polyunsaturated phosphatidylcholine, glycolipids and other polyunsaturated phosphatidyl nutrients derived from soybean. Bifido and Lactobacillus Bacterium Growth Media - foods and bacterial growth factors to Support microflora colonies including rice bran extract, arginine, beet root fiber, blackstrap molasses, glycine, magnesium sulfate, para-amino-benzoate, leek, pantethine (bifido growth factor), taurine, garlic, calcium borogluconate, potassium citrate, calcium sulfate, spirulina, bromelain, natural Vitamin E, calcium ascorbate, alpha-lipoic acid, oligosaccharides, B-6, niacinamide, riboflavin, inositol, niacin, calcium pantothenate, thiamin, B-12, folic acid, chromium picolinate	
Mitochondria Pro Regulator™ Calcium (as phosphate/sulfate/pyruvate), Phosphorus (as calcium phosphate), Magnesium (as sulfate)	260 mg *
Krebs Cycle Glucose Absorb™ Alpha-Ketoglutaric Acid, L-Tyrosine	180 mg *
RN Fatty Acid Metabolizer™ L-Carnitine-L-Tartrate, Pantethine (as coenzyme A precursor)	140 mg *

* Daily Value is not established.

Other Ingredients

Microcrystalline cellulose, croscarmellose, sodium, methyl cellulose, vegetable magnesium stearate, silica.

Suggested Use

Two tablets with each meal (6 tablets per day) for the first two months, and one tablet with each meal in month 3 and beyond. For severe fatigue, increase to three tablets with each meal (9 tablets per day) for the first two months, and one tablet with each meal in month 3 and beyond. **It is important to keep with the protocol for the first two months so that enough cell membranes are repaired --- which will allow the patient to feel the difference.**

Cautions

None known

Research Papers

1. Increased Energy & Improved Mitochondrial Function, *J Chronic Fatigue Syndrome* 2003; 11(3): 23-36
2. Results of a Study to Evaluate the Use of NT Factor to Reduce Adverse Effects of Chemotherapy, *Journal of the American Nutraceutical Association* Vol. 3 No. 2000, 17-25